Project Grant R01CA289492
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$705K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90089, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $1,620,203 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of Southern California (USC) on July 23, 2024. The purpose of this 5-year project is to identify factors associated with prostate cancer progression and survival in African American men through the RESPOND cohort. The project aims to:
Examine multi-level provider, geospatial, and personal factors that define access to care and their...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $613,220 to the University of Southern California (USC) to conduct a comprehensive investigation of the contribution of germline copy number variations (CNVs) to the susceptibility of aggressive prostate cancer in men of African and European ancestry.
The study aims to leverage existing genome-wide association studies (GWAS), whole-exome sequencing (WES), and whole-genome...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $539,633 to support research at Albert Einstein College of Medicine focused on investigating the role of aberrant androgen receptor signaling in prostate cancer development and progression, particularly in the African American population. The project aims to leverage new animal models and advanced techniques like single-cell RNA sequencing to study how genetic factors like shorter...
The National Cancer Institute (NCI) awarded a $432,304 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of Columbia University in the City of New York, Health Sciences Division, to develop enhanced cancer risk prediction models for underrepresented Black and Hispanic populations. The 5-year project, beginning January 3, 2025, aims to create novel data integration methods that effectively leverage diverse data sources, including electronic...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), is providing $475,759 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to investigate methods for early detection of prostate cancer in African American men.
The key products or services being delivered under this 2-year award include:
Benchmarking and optimizing protocols to detect prostate cancer at various disease...
This $659,498 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to investigate racial disparities in the mechanisms of prostate cancer metastasis, with a primary focus on examining the roles of the FGFR3 signaling pathway and oxidative phosphorylation (OXPHOS) activity. The award was granted to Emory University, with sub-awards to Johns Hopkins University and Morehouse School of Medicine to assist with various...
The National Cancer Institute (NCI) awarded a $680,433 project grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at improving prognostic estimation and understanding of prostate cancer biology and heterogeneity. The 5-year project seeks to:
Evaluate the competitive and additive relationships between standard-of-care genomic expression and pathology artificial...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $156,000.00 in funding to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, to conduct whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic castration-resistant prostate cancer (mCRPC). The goal is to identify race-specific mutational signatures and evaluate their associations with...
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), aims to investigate the relationship between vitamin D deficiency, prostate androgen hormones, and the increased risk of aggressive prostate cancer in African American men. The five-year, $366,242 grant awarded to the University of Illinois will fund a research project that combines analysis of patient-derived models, mouse studies, and clinical samples to examine the role of...
This Project Grant award of $716,672 from the National Cancer Institute's (NCI) Cancer Cause and Prevention Research program (CFDA 93.393) aims to develop new personalized colorectal cancer (CRC) risk prediction tools tailored for Black Americans. The 4-year project will:
(A) Develop and validate new CRC risk prediction models for Black men and women based on lifestyle, demographic, social, and screening factors;
(B) Build dynamic risk models using advanced statistical and machine learning...